Immunic, inc. (VTL)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash flows from operating activities:
Net loss

-34,933

-11,542

-52,078

-40,969

-52,023

-47,667

-32,718

-6,701

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

50

15

998

1,808

1,328

1,087

799

651

Gain on sale of ELAD Assets

329

0

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

382

Revaluation of preferred stock warrant liabilities

-

-

-

-

-

-

-

-180

Revaluation of future purchase rights liabilities

-

-

-

-

-

2,600

-1,306

3,101

(Gain) loss on disposal of equipment

26

-1

-

-

-

-

-

7

Fixed Asset Impairment

-

-

0

0

-

-

-

-

Stock-based compensation

6,512

0

5,480

4,678

4,029

2,510

948

144

Contingent payment settled in common stock

1,540

0

256

0

0

-

-

-

Other

-

-

1

-85

0

7

1

-41

Changes in operating assets and liabilities:
Other current assets and prepaid expenses

2,224

-218

-165

232

-143

-279

1,141

242

Accounts payable

-462

1,200

287

-459

281

46

-91

-219

Other liabilities

1,102

1

4,490

-587

-3,584

5,396

2,266

-12

Accrued expenses and other liabilities

225

369

6

-98

-126

131

-16

-

Net cash used in operating activities

-28,545

-9,738

-40,397

-35,774

-

-

-

-

Net cash used in operating activities

-

-

-

-

-49,952

-40,825

-28,648

-9,244

Cash flows from investing activities:
Purchases of property and equipment

55

32

685

556

2,340

1,409

1,484

261

Purchases of short-term investments

-

-

-

-

-

-

2,999

13,992

Sales of short-term investments

-

-

-

-

-

-

17,000

-

Cash distribution in connection with ELAD Assets sale

75

0

0

-533

-1,059

631

608

355

Proceeds from sale of ELAD assets

2,475

0

-

-

-

-

-

-

Cash acquired in connection with the Transaction

8,151

0

-

-

-

-

-

-

Proceeds from sale of equipment

40

0

7

2

0

0

-

20

Net cash used in investing activities

10,536

-32

-678

-21

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-1,281

-2,040

11,909

-14,588

Cash flows from financing activities:
Proceeds from issuance of common stock in pre-closing financing, net of issuance costs of $61

29,965

0

5

32

515

852

135

-

Proceeds from public offering of common stock, net of issuance costs of $37

5,200

0

-

-

-

-

-

-

Principal payments on term loan

-

-

-

-

-

-

-

533

Proceeds from issuance of preferred stock

0

19,256

37,998

12,355

32,189

87,899

0

-

Proceeds from stock subscription not yet issued

-

-

-

-

-

18,167

53,195

21,100

Proceeds from debt, net of issuance costs

-

-

-

-

-

-

-

6,934

Deferred financing costs

270

0

19

13

283

0

3,112

-

Net cash provided by financing activities

34,895

19,256

37,984

12,374

-

-

-

-

Proceeds from early exercise of stock options

-

-

-

-

-

-

227

-

Net cash provided by financing activities

-

-

-

-

32,421

106,918

50,445

27,501

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-589

-918

-

-

-

-

-

-

Net change in cash, cash equivalents and restricted cash

16,297

8,568

-

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Valuation of future purchase rights upon issuance

-

-

-

-

-

-

1,294

3,101

Accretion to redemption value of redeemable convertible preferred stock

-

-

-

-

-

4,410

6,303

942

Amortization of deemed dividend

-

-

-

-

-

4,744

64

-

Purchases of property and equipment included in liabilities

-

-

16

41

9

277

170

502

Cash paid for interest

0

1

1

0

39

0

394

-

Cash paid for interest

-

-

-

-

-

-

-

32

Supplemental disclosure of noncash investing and financing activities:
Stock issuance and deferred financing costs included in accounts payable and accrued expenses

20

0

-

-

-

-

-

-

Conversion of debt for redeemable convertible preferred stock

-

-

-

-

-

-

-

7,296

Conversion of convertible preferred stock to common stock

37,193

0

-

-

-

110,796

0

54,715

Conversion of convertible preferred stock to common stock

39,400

0

-

-

-

-

-

-

Purchase of property and equipment included in accounts payable

19

0

-

-

-

-

-

-

Reconciliation of cash, cash equivalents and restricted cash:
Effect of exchange rate changes on cash and cash equivalents

-

-

1

-4

-10

-1

3

5

Net change in cash and cash equivalents

-

-

-3,090

-23,425

-18,822

64,052

33,709

3,674

Leasehold improvements paid for by landlord

-

-

-

-

-

-

478

-

Change in stock option early exercise repurchase liability

-

-

0

23

108

104

0

-